Myriad Pharmaceuticals cancer news
Myriad restructured and reduced headcount by 21 (13%) to about 140 to focus on its cancer pipeline. The company's lead cancer compound is Azixa, a small molecule microtubule destabilizing apoptosis-inducer in Phase II testing for metastatic melanoma and recurrent glioblastoma multiforme. Myriad also has MPC-3100, a fully-synthetic, non-geldanamycin small molecule inhibitor of heat shock protein ( Hsp90) in Phase I testing for refractory or relapsed solid and blood tumors; and MPC-9528, a small molecule inhibitor of nicotinamide phosphoribosyl transferase (NamPRT) in preclinical testing for cancer.
The cuts came from commercial operations and included SVP of Development Ed Swabb and VP of Human Resources Barbara Berry. The company suspended further development of its HIV program and plans to seek partners for the compounds, including MPC-4326, an oral formulation of a viral maturation inhibitor that is in Phase II testing. ...